Amgen, member of CataloniaBio & HealthTech, has completed the acquisition of Horizon Therapeutics plc for $116.50 per action, representing a transaction value of approximately $27.8M. 

"Today marks an exciting milestone as we welcome Horizon employees to begin working together to serve even more critically diseases patients around the world," said Robert A. Bradway, Amgen's Chairman and Chief Executive Officer. "Our business is experiencing a moment of great boost, and the addition of Horizon to Amgen will further position our company as a leader in a broader variety of diseases." 

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address the critical needs of people affected by rare, autoimmune and severe inflammatory diseases. 

The strategic and financial rationale for the acquisition includes aligning the acquisition with Amgen's strategy to deliver innovative drugs that make a meaningful difference to patients suffering from serious diseases. Also strengthen Amgen's leading inflammation portfolio by adding first-in-class as well as early-stage drugs to treat rare inflammatory diseases and leverage Amgen's first-in-class capabilities in research and biologics development, process development and production, as well as Amgen's presence in more than 100 countries around the world. 

"We are looking forward to enhancing the important work already done by Horizon", says Fina Lladós, General Director of Amgen Iberia. "This acquisition helps us further our mission to serve patients by transforming the promise of science and biotechnology with therapies for rare diseases that have the power to improve people's health or save lives."